H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX)

​Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock with a $31 price target. Earlier, on January 14, BTIG reiterated a Buy rating on the stock with a $30 price target.

Analysts at BTIG noted that the bullish sentiment follows the company’s recently highlighted key 2026 objectives. Management highlighted that their bexdeg, which is a BTK degrader for relapsed chronic lymphocytic leukemia, is progressing as planned. Moreover, the phase 3 study is expected to feature a head-to-head comparison against Pirtobrutinib, the newest approved BTK inhibitor. The study will prove superiority and match emerging care standards.

In addition, Nurix Therapeutics, Inc. (NASDAQ:NRIX) is also advancing its immunology assets, with Phase 1 data for the Gilead-partnered IRAK4 degrader due in 2026. The firm highlighted that the company holds $664 million in cash, which is sufficient to fund operations into 2028.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes innovative small molecules and antibody therapies as a novel treatment approach for inflammatory conditions, cancer, and other challenging diseases.​

While we acknowledge the potential of NRIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.